Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of LBL-024 combination therapy in advanced solid tumors
CTR20260332Phase 2Active
- Sponsor
- Leads Biolabs
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Leads Biolabs. Started Apr 2026; status: active.
02
Drugs
opamtistomig
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20260332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260332.